Product Description: Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013 Jan;73(1):75-97./[2]Nesbitt A, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007 Nov;13(11):1323-32./[3]Kosekli MA, et al. Effects of Certolizumab on Cerulein-Induced Acute Pancreatitis in Rats. Pancreas. 2016 Sep;45(8):1120-5.
CAS Number: 428863-50-7
Molecular Weight: N/A
Compound Purity: 99.30
Research Area: Inflammation/Immunology
Solubility: H2O
Target: TNF Receptor
English
Deutsch
